The pharmacological profile of the low molecular weight heparin 21-23 in man: anticoagulant, lipolytic and protamine reversible effects.
The anticoagulant, lipolytic and protamine reversible effects of high doses of low molecular weight (LMW) heparin 21-23 and unfractionated heparin were compared in man. 7,500 units of each heparin were applied, which corresponds to 90 mg LMW heparin and 48 mg unfractionated heparin. The anticoagulant properties of the LMW heparin are characterized by a doubled half life of factor Xa activity, smaller influence on aPTT and thrombin after intravenous (i.v.) and subcutaneous (s.c.) injection, and higher bioavailability of factor Xa activity after s.c. administration (90% versus 15%). Protamine chloride completely neutralizes the effect on aPTT and thrombin and reduces the anti factor Xa activity by 60%. The bleeding time is prolonged by both normal and LMW heparin by 20%. This effect is normalized by protamine chloride, too. Thrombelastography with recalcified whole blood demonstrates that protamine chloride shortens but not completely normalizes the coagulation time in presence of either unfractionated or LMW heparin. The half life of lipoprotein lipase (LPL) activity is 60 min after i.v. administration of unfractionated heparin and 120 min with LMW heparin. Although the release of lipases (LPL and HTGL) is higher after i.v. and s.c. administration of the LMW heparin they do not induce higher releases of free fatty acids. This indicates that the lipolytic activity of this LMW heparin and unfractionated heparin is similar. The results show an improved anticoagulant pharmacological profile of this LMW heparin as compared to unfractionated heparin. Protamine normalizes the anticoagulant effects of LMW heparin with exception of a residual anti factor Xa activity and normalizes the changes of bleeding time and thrombelastography.
Harenberg
J
J
1st Department of Medicine, Faculty of Clinical Medicine Mannheim, University of Heidelberg, Mannheim, FRG.
Stehle
G
G
Dempfle
C E
CE
von Hodenberg
E
E
Heene
D L
DL
D000328:Adult; D000925:Anticoagulants; D001777:Blood Coagulation / Q000187:drug effects; D065427:Factor Xa Inhibitors; D005230:Fatty Acids, Nonesterified / Q000378:metabolism; D006495:Heparin, Low-Molecular-Weight / Q000494:pharmacology*; D006801:Humans; D008049:Lipase / Q000378:metabolism; D008053:Lipid Mobilization / Q000187:drug effects; D008071:Lipoprotein Lipase / Q000378:metabolism; D010314:Partial Thromboplastin Time; D011479:Protamines / Q000494:pharmacology; D013917:Thrombin / Q000502:physiology
D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D005230:Fatty Acids, Nonesterified; D006495:Heparin, Low-Molecular-Weight; D011479:Protamines; D008049:Lipase; D008071:Lipoprotein Lipase; D013917:Thrombin